deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT02655016

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Sponsor: European Network of Gynaecological Oncological Trial Groups (ENGOT)

Conditions Ovarian Neoplasms
Interventions Niraparib Placebo
Updated 31 times since 2017 Last updated: Feb 17, 2026 Started: Jul 11, 2016 Primary completion: May 17, 2019 Completion: May 29, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Ovarian Neoplasms, this trial is ongoing. The trial is conducted by European Network of Gynaecological Oncological Trial Groups (ENGOT) and has accumulated 31 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Jul 2020 · 23 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Mar 2023 · 3 months · monthly snapshot~Mar 2023 – ~May 2024 · 14 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jul 2025 · 8 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 3 months · monthly snapshot

Change History

31 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Feb 2026 — Mar 2026 [monthly]

    Active Not Recruiting PHASE3

  3. Nov 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 26 earlier versions

  1. Nov 2024 — Jul 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  4. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE3

  6. Dec 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  9. Nov 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE3

  10. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE3

  11. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  12. Feb 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  13. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  14. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  15. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  16. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  17. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  18. Aug 2018 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  19. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  20. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  21. Feb 2018 — May 2018 [monthly]

    Recruiting PHASE3

  22. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

  23. Jun 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  24. Mar 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  25. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  26. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • European Network of Gynaecological Oncological Trial Groups (ENGOT)
  • Gynecologic Oncology Group
  • Myriad Genetics, Inc.
  • Tesaro, Inc.
Data source: Tesaro, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aalborg, Denmark , Angers, France , Atlanta, United States , Badalona, Spain , Baltimore, United States , Barcelona, Spain , Basel, Switzerland , Berlin, Germany , Bern, Switzerland and 94 more locations